. 1999 Jan;12(1):40–79. doi: 10.1128/cmr.12.1.40

TABLE 2.

Azole antifungal agents for systemic mycoses

Clinical use	Ketoconazole	Itraconazole	Fluconazole
Aspergillosis		√^a
Candidiemia		√^b ^c	√
Cryptococcosis		√^d	√
Blastomycosis	√^a ^d ^e	√^a	√^d
Histoplasmosis	√^a ^d ^e	√^a	√^b
Coccidioidomycosis	√^a	√	√
Paracoccidioidomycosis	√^d	√	√^b
Sporotrichosis		√	√^b
Pseudallescheriasis	√^d	√

Not for meningeal infection.

Promising, but clinical studies needed.

Lack of i.v. formulation at present limits use in seriously ill patients.

Second-line azole.

Nonimmunosuppressed hosts only.